Regulatory FDA clears Orca’s cell therapy Tregzi for GvHD PharmaphorumOrca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.HematologyRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) Pharmaphorum Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants. Hematology Read full story Post navigation Previous: Lilly’s Jaypirca Wins CHMP Opinion for CLL Across All LinesNext: Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail Related Stories Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026
